1.2Methylsulfinyl group at X
The substituent has the connectivity core–S(=O)–CH3. Sulfur connects the methyl group to the core, and the sulfoxide oxygen provides a hydrogen-bond acceptor.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The substituent has the connectivity core–S(=O)–CH3. Sulfur connects the methyl group to the core, and the sulfoxide oxygen provides a hydrogen-bond acceptor.
The bridge has the structure –C≡C–, with each carbon bonded to one adjoining fragment. The triple bond holds the two attachment bonds on a nearly linear axis.
L2 bonds to one bridgehead carbon of the saturated five-carbon cage. Three methylene bridges connect the two bridgeheads and constrain the cage geometry.
Both fragments bond to the carbonyl carbon in a fragment–C(=O)–fragment arrangement. The carbonyl carbon gives the two attachment bonds a local angle of approximately 120°, and the oxygen provides a hydrogen-bond acceptor.
The amide nitrogen bonds to the ring carbon opposite the oxygen in the four-membered oxetane ring. That carbon fixes the attachment point, and the ring oxygen provides a hydrogen-bond acceptor.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A sulfone group replaces the thioether at Z, giving a —S(=O)₂— bridge between the same two attachment atoms. The corresponding thioether serves as the starting material, and a peracid oxidizes its sulfur through the sulfoxide to the sulfone. Liquid chromatography tracks consumption of the starting material, and high-resolution mass spectrometry checks for incorporation of two oxygen atoms.
A 384-well plate holds tumor cells in 40 microliters of medium per well. The tricyclic compound is tested in triplicate at eight concentrations spaced by threefold dilutions from 10 micromolar, with the same vehicle concentration in all wells. After 72 hours, a luminescent ATP assay measures viable cell mass relative to vehicle-treated wells.
Three dissolution vessels each hold 900 milliliters of medium at 37 degrees Celsius, with one vessel each at pH 1.2, 4.5, and 6.8. A paddle rotates at 50 revolutions per minute in each vessel, and each vessel receives a tablet from the same batch containing the tricyclic compound. Samples collected at 5, 15, 30, and 60 minutes are filtered and analyzed by liquid chromatography to calculate the fraction dissolved.
A microfluidic chip holds tumor spheroids in a hydrogel chamber adjacent to a perfusion channel. A syringe pump supplies medium containing the tricyclic compound, which diffuses from the channel into the hydrogel. A second chip receives vehicle, and fluorescence imaging measures the fraction of viable cells in spheroids from both chips.
Software stores the tricyclic framework as a molecular graph with labeled attachment atoms for L1, Z, and the side groups. It joins fragments at those atoms, checks bond orders and valences, and removes duplicate structures using canonical molecular identifiers. It computes molecular mass and polar surface area for each structure and exports the structures and descriptors in a searchable table.
L1 is a two-carbon alkylene bridge with the connectivity –CH2–CF2–. Two fluorine atoms serve as the R1 substituents on the same bridge carbon.
A pendant substituent on the R2 group has the structure –CH2–C(=O)–N(CH3)2. One methylene separates the attachment point from the amide carbonyl, and both substituents on the amide nitrogen are methyl groups.
R2d is cyclopropylmethyl, with one methylene between the attachment point and a saturated three-membered carbon ring. In an amide of the form –C(=O)–NH–CH2–cyclopropyl, that methylene bonds directly to the amide nitrogen.
A phenyl group bears –OCF3 para to its point of attachment to the adjoining fragment. The ether oxygen connects the phenyl ring to a single carbon bearing three fluorine atoms.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
If one or more of the substituents comprises a monocyclic or bicyclic ring system, which is mono- or polysubstituted, this may preferably be substituted with optionally 1, 2, 3, 4 or 5, particularly preferably with optionally 1, 2 or 3, substituents which may be mutually independently selected from the group consisting of F, Cl, Br, I, —CN, —NO2, —OH, —SH, —NH2, oxo (═O), thioxo (═S), —C(═O)—OH, C1-5 alkyl, —C2-5 alkenyl, —C2-5 alkynyl, —C≡C—Si(CH3)3, —C≡C—Si(C2H5)3, —(CH2)—OA · US 2009/0176756 A1 · ¶ 35
The term “heteroalkylene” denotes an alkylene chain as described above in which one or more C atoms have in each case been replaced by a heteroatom mutually independently selected from the group consisting of oxygen, sulfur and nitrogen (NH). Heteroalkylene groups may preferably comprise 1, 2 or 3 heteroatom(s), particularly preferably one heteroatom, selected from the group consisting of oxygen, sulfur and nitrogen (NH) as chain link(s).A · US 2009/0176756 A1 · ¶ 54
The term “alkylene,” as used herein, alone or in combination, refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon attached at two or more positions, such as methylene (—CH2—).B · US 9,675,584 B2 · ¶ 178
Particularly preferably, alkylene, alkenylene, alkynylene, heteroalkylene or heteroalkenylene groups may be substituted with 1, 2 or 3 substituents mutually independently selected from the group consisting of phenyl, F, Cl, Br, I, —NO2, —CN, —OH, —O-phenyl, —SH, —S-phenyl, —NH2, —N(CH3)2, —N(C2H5)2 and —N(CH3)(C2H5), wherein the phenyl residue may be substituted with 1, 2, 3, 4 or 5 substituents mutually independently selected from the group consisting of F, Cl, Br, I, —OH, —A · US 2009/0176756 A1 · ¶ 58
R2 is chosen from cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, any of which may be optionally substituted by one or more substituents chosen from lower alkyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, aryl, aralkyl, lower alkoxy, lower haloalkoxy, carboxy, cyano, hydrogen, halogen, hydroxy, amino, lower alkylamino, amido, nitro, sulfonate, and sulfonic acid;B · US 9,675,584 B2 · claim 1
The term “heteroalkylene” denotes an alkylene chain as described above in which one or more C atoms have in each case been replaced by a heteroatom mutually independently selected from the group consisting of oxygen, sulfur and nitrogen (NH). Heteroalkylene groups may preferably comprise 1, 2 or 3 heteroatom(s), particularly preferably one heteroatom, selected from the group consisting of oxygen, sulfur and nitrogen (NH) as chain link(s).A · US 2009/0176756 A1 · ¶ 54
The term “alkylene,” as used herein, alone or in combination, refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon attached at two or more positions, such as methylene (—CH2—).B · US 9,675,584 B2 · ¶ 178
R2 is chosen from cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, any of which may be optionally substituted by one or more substituents chosen from lower alkyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, aryl, aralkyl, lower alkoxy, lower haloalkoxy, carboxy, cyano, hydrogen, halogen, hydroxy, amino, lower alkylamino, amido, nitro, sulfonate, and sulfonic acid;B · US 9,675,584 B2 · claim 1
R5 and R6 are each independently chosen from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl may be optionally substituted by one or more substituents chosen from lower alkyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower perhaloB · US 9,675,584 B2 · claim 1
R5 and R6 are each independently chosen from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl may be optionally substituted by one or more substituents chosen from lower alkyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower perhaloB · US 9,675,584 B2 · claim 1
If one or more of the substituents comprises a monocyclic or bicyclic ring system, which is mono- or polysubstituted, this may preferably be substituted with optionally 1, 2, 3, 4 or 5, particularly preferably with optionally 1, 2 or 3, substituents which may be mutually independently selected from the group consisting of F, Cl, Br, I, —CN, —NO2, —OH, —SH, —NH2, oxo (═O), thioxo (═S), —C(═O)—OH, C1-5 alkyl, —C2-5 alkenyl, —C2-5 alkynyl, —C≡C—Si(CH3)3, —C≡C—Si(C2H5)3, —(CH2)—OA · US 2009/0176756 A1 · ¶ 35
R3 is chosen from hydrogen, halogen, trifluoromethyl, hydroxy, C1-C5 alkyl, and C1-C5 alkoxy, wherein C1-C5 alkyl and C1-C5 alkoxy may be optionally substituted by one or more substituents chosen from lower alkyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, aryl, aralkyl, lower alkoxy, lower haloalkoxy, carboxy, cyano, halogen, hydroxy, amino, lower alkylamino, amido, nitro, sulfonate, and sulfonic aciB · US 9,675,584 B2 · claim 1
If one or more of the substituents comprises a monocyclic or bicyclic ring system, which is mono- or polysubstituted, this may preferably be substituted with optionally 1, 2, 3, 4 or 5, particularly preferably with optionally 1, 2 or 3, substituents which may be mutually independently selected from the group consisting of F, Cl, Br, I, —CN, —NO2, —OH, —SH, —NH2, oxo (═O), thioxo (═S), —C(═O)—OH, C1-5 alkyl, —C2-5 alkenyl, —C2-5 alkynyl, —C≡C—Si(CH3)3, —C≡C—Si(C2H5)3, —(CH2)—OA · US 2009/0176756 A1 · ¶ 35
R3 is chosen from hydrogen, halogen, trifluoromethyl, hydroxy, C1-C5 alkyl, and C1-C5 alkoxy, wherein C1-C5 alkyl and C1-C5 alkoxy may be optionally substituted by one or more substituents chosen from lower alkyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, aryl, aralkyl, lower alkoxy, lower haloalkoxy, carboxy, cyano, halogen, hydroxy, amino, lower alkylamino, amido, nitro, sulfonate, and sulfonic aciB · US 9,675,584 B2 · claim 1
R2 is chosen from cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, any of which may be optionally substituted by one or more substituents chosen from lower alkyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, aryl, aralkyl, lower alkoxy, lower haloalkoxy, carboxy, cyano, hydrogen, halogen, hydroxy, amino, lower alkylamino, amido, nitro, sulfonate, and sulfonic acid;B · US 9,675,584 B2 · claim 1
An empty cell means only that no passage was reproduced there.
There is a worldwide need for effective pain treatments.A · US 2009/0176756 A1 · ¶ 2
Moreover, they are frequently insufficiently effective in the case of neuropathic pain, suffered in particular by tumour patients.A · US 2009/0176756 A1 · ¶ 3
Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease.B · US 9,675,584 B2 · ¶ 2
Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.B · US 9,675,584 B2 · ¶ 2
patent.fyi, US 2026/0355216 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355216/, SHA-256 508c2e979a57780998c44e3daec0b60124cd21b597020e3cf71b0a4f4caad770